Personalized care approaches to hepatitis C therapy: recent advances and future directions

References

• Organization WH. Hepatitis C. 2022 [05/apr/2023]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
   Google Scholar
• Ghany MG, Morgan TR, AIHCG P. Hepatitis C guidance 2019 update: American association for the study of liver diseases–infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. 10.1002/hep.31060
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015 Jan;61(1):77–87.
   PubMed Web of Science ®Google Scholar
• Scotto R, Buonomo AR, Moriello NS, et al. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection. Rev Recent Clin Trials. 2019;14(3):173–182. 10.2174/1574887114666190306154650
   PubMed Web of Science ®Google Scholar
• Auty SG, Griffith KN, Shafer PR, et al. Improving access to high-value, high-cost medicines: the use of subscription models to treat hepatitis C using direct-acting antivirals in the United States. J Health Polit Policy Law. 2022 Dec 1;47(6):691–708. doi: 10.1215/03616878-10041121
   PubMed Web of Science ®Google Scholar
• Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014 Apr;58(7):928–936.
   PubMed Web of Science ®Google Scholar
• Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer. 2016 May 16;11(1):24.
   PubMedGoogle Scholar
• Chan HLY, Chen CJ, Omede O, et al. The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm: volume 4. J Viral Hepat. 2017;24(S2):25–43. doi: 10.1111/jvh.12760
   PubMedGoogle Scholar
• Wyles D, Mangia A, Cheng W, et al. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018;23(3):229–238. doi: 10.3851/IMP3181
   PubMed Web of Science ®Google Scholar
• Howe AYM, Rodrigo C, Cunningham EB, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep. 2022;4(5):100462. doi: 10.1016/j.jhepr.2022.100462
   PubMedGoogle Scholar
• Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic hepatitis C infection-A brief review of literature. J Family Med Prim Care. 2020 Feb;9(2):531–538. doi: 10.4103/jfmpc.jfmpc_943_19
   PubMedGoogle Scholar
• Chen CY, Huang CF, Cheng PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021 Jun;41(6):1265–1277.
   PubMed Web of Science ®Google Scholar
• Nguyen Thi Thu P, Ngo Thi Quynh M, Pham Van L, et al. Determination of risk factors associated with the failure of 12 weeks of direct-acting antiviral therapy in patients with hepatitis C: a prospective study. Biomed Res Int. 2022;2022:1–10. doi: 10.1155/2022/6054677
   Web of Science ®Google Scholar
• Mücke MM, Mücke VT, Lange CM, et al. Managing hepatitis C in patients with the complications of cirrhosis. Liver Int. 2018;38(S1):14–20. doi: 10.1111/liv.13636
   PubMedGoogle Scholar
• Fabrizi F, Messa P. Treatment choices for hepatitis C in patients with kidney disease. Clin J Am Soc Nephrol. 2018;13(5):793–795. doi: 10.2215/CJN.12621117
   PubMed Web of Science ®Google Scholar
• Bandera A, Lorenzini P, Taramasso L, et al. The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA foundation cohort. J Viral Hepat. 2021 May;28(5):779–786.
   PubMed Web of Science ®Google Scholar
• Patel SV, Jayaweera DT, Althoff KN, et al. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLoS One. 2020;15(2):e0228847. doi: 10.1371/journal.pone.0228847
   PubMed Web of Science ®Google Scholar
• Bhatia HK, Singh H, Grewal N, et al. Sofosbuvir: a novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014 Oct;5(4):278–284.
   PubMedGoogle Scholar
• Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22(12):1011–1019. doi: 10.1111/jvh.12435
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607. doi: 10.1056/NEJMoa1512610
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–2617. doi: 10.1056/NEJMoa1512612
   PubMed Web of Science ®Google Scholar
• Taylor JG, Appleby T, Barauskas O, et al. P0899: preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol. 2015 Apr 01;62:S681.
   Web of Science ®Google Scholar
• Kirby B, Yang J, Yang C, et al. P0861: evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteers. J Hepatol. 2015 Apr 01;62:S663.
   Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017 Jul;153(1):113–122.
   PubMed Web of Science ®Google Scholar
• Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 Jun 1;376(22):2134–2146. doi: 10.1056/NEJMoa1613512
   PubMed Web of Science ®Google Scholar
• Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother. 2018;62(1):e01620–17. doi: 10.1128/AAC.01620-17
   PubMed Web of Science ®Google Scholar
• Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61(5):e02558–16. doi: 10.1128/AAC.02558-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369. doi: 10.1056/NEJMoa1702417
   PubMed Web of Science ®Google Scholar
• Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417–426. doi: 10.1016/j.cgh.2017.09.027
   PubMed Web of Science ®Google Scholar
• Brown RS, Jr., Buti M, Rodrigues L, et al. Glecaprevir/Pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020 Mar;72(3):441–449.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014 May;23(5):719–728.
   PubMed Web of Science ®Google Scholar
• Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedchem. 2013 Dec;8(12):1930–1940.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann internal med. 2015;163(1):1–13. doi: 10.7326/M15-0785
   PubMed Web of Science ®Google Scholar
• Wei L, Zhdanov K, Burnevich E, et al. Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial. J Hepatol. 2017;66(1):S529. doi: 10.1016/S0168-8278(17)31460-5
   Web of Science ®Google Scholar
• Negro F. Natural history of hepatic and extrahepatic hepatitis C virus diseases and impact of interferon-free HCV therapy. Cold Spring Harb Perspect Med. 2020 Apr 1;10(4):a036921.
   PubMed Web of Science ®Google Scholar
• Mohd Suan MA, Said SM, Lim PY, et al. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: a case–control study. PloS One. 2019;14(10):e0224459. 10.1371/journal.pone.0224459
   PubMed Web of Science ®Google Scholar
• Demirchyan A, Sahakyan S, Aslanyan L, et al. Prevalence and risk factors of hepatitis C virus infection in Armenia, 2021. Eur J Public Health. 2022;32(Supplement_3). doi: 10.1093/eurpub/ckac131.392
   Google Scholar
• Shalimar PS, Gupta H, Gupta H, et al. A systematic review of risk factors for hepatitis C virus infection among low-risk population in India. J Clin Exp Hepatol. 2022 Nov;12(6):1438–1444.
   PubMed Web of Science ®Google Scholar
• Kondili LA, Gamkrelidze I, Blach S, et al. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int. 2020;40(7):1545–1555. doi: 10.1111/liv.14408
   PubMed Web of Science ®Google Scholar
• Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016 Sep 14;22(34):7824–7840. doi: 10.3748/wjg.v22.i34.7824
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Huneau A, Verleene A, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69(4):785–792. doi: 10.1016/j.jhep.2018.05.027
   PubMed Web of Science ®Google Scholar
• Jhaveri R. Screening for hepatitis C virus: how universal is universal? Clin Ther. 2020 Aug;42(8):1434–1441. doi: 10.1016/j.clinthera.2020.06.012
   PubMed Web of Science ®Google Scholar
• Graham CS, Trooskin S. Universal screening for hepatitis C virus infection: a step toward elimination. JAMA. 2020;323(10):936–937. doi: 10.1001/jama.2019.22313
   PubMed Web of Science ®Google Scholar
• Carey I, Christiana M, Marie-Ange M, et al. Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive. J Viral Hepat. 2022 Dec;29(12):1079–1088.
   PubMed Web of Science ®Google Scholar
• Shih STF, Cheng Q, Carson J, et al. Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis. Lancet Reg Health West Pac. 2023;36. doi: 10.1016/j.lanwpc.2023.100750
   Google Scholar
• Chevaliez S, Wlassow M, Volant J, et al. Assessing molecular point-of-care testing and dried blood spot for hepatitis C virus screening in people who inject drugs. Open Forum Infect Dis. 2020 Jun;7(6):ofaa196.
   PubMed Web of Science ®Google Scholar
• Cousien A, Tran VC, Deuffic-Burban S, et al. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2016 Apr;63(4):1090–101.
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac E, Capron D, Castelain S, et al. Personalized therapy for chronic viral hepatitis C in the naive patient: how can we optimize treatment duration as a function of viral genotype? Eur J Intern Med. 2007 Nov;18(7):510–515.
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Colombatto P, Bonino F. Personalized therapy in chronic viral hepatitis. Mol Aspects Med. 2008 Feb;29(1–2):103–111. doi: 10.1016/j.mam.2007.09.015
   PubMed Web of Science ®Google Scholar
• Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop. 2010 May;43(3):217–223.
   PubMed Web of Science ®Google Scholar
• Simoes P, Asaad A, Abed J, et al. Effect of gender on the response to hepatitis C treatment in an inner-city population. Women's Health Issues. 2015 May;25(3):289–293.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015 Dec 31;373(27):2599–2607. doi: 10.1056/NEJMoa1512610
   PubMed Web of Science ®Google Scholar
• Wyles D, Bräu N, Kottilil S, et al. Sofosbuvir and Velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clinical Infectious Diseases. 2017;65(1):6–12. doi: 10.1093/cid/cix260
   PubMed Web of Science ®Google Scholar
• Lawitz E, Flisiak R, Abunimeh M, et al. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020 May;40(5):1032–1041.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019 Mar;70(3):379–387.
   PubMed Web of Science ®Google Scholar
• Berg T, Naumann U, Stoehr A, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German hepatitis C-Registry. Aliment Pharmacol Ther. 2019 Apr;49(8):1052–1059.
   PubMed Web of Science ®Google Scholar
• Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018 Aug;69(2):293–300.
   PubMed Web of Science ®Google Scholar
• Flamm S, Mutimer D, Asatryan A, et al. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2/3 analysis. J Viral Hepat. 2019 Mar;26(3):337–349.
   PubMed Web of Science ®Google Scholar
• Larney S, Madden A, Marshall AD, et al. A gender lens is needed in hepatitis C elimination research. Int J Drug Policy. 2022 May;103:103654. doi: 10.1016/j.drugpo.2022.103654
   PubMed Web of Science ®Google Scholar
• Dion K, Chiodo L, Whynott L, et al. Exploration of the unmet health care needs of people who inject drugs. J Am Assoc Nurse Pract. 2020 Jan;32(1):60–69.
   PubMed Web of Science ®Google Scholar
• Couto ECC, Salom CL, Dietze P, et al. Frequent experience of discrimination among people who inject drugs: links with health and wellbeing. Drug Alcohol Depend. 2018 Sep 1;190:188–194. doi: 10.1016/j.drugalcdep.2018.06.009
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ, Altice FL. Reinfection and risk behaviors after treatment of hepatitis C virus infection in persons receiving opioid agonist therapy. Ann internal med. 2022;175(9):1221–1229. doi: 10.7326/M21-4119
   PubMed Web of Science ®Google Scholar
• Falcato L, Bernardini C, Bruggmann P. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland. Int J Drug Policy. 2021 Oct 01;96:103434. doi: 10.1016/j.drugpo.2021.103434
   PubMed Web of Science ®Google Scholar
• Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153–161.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ, Alami NN, et al. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy. 2019 Apr;66:73–79. doi: 10.1016/j.drugpo.2019.01.011
   PubMed Web of Science ®Google Scholar
• Grebely J, Read P, Cunningham EB, et al. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): an open-label, single-arm, phase 4, multicentre trial. Health Sci Rep. 2020;3(2):e151. doi: 10.1002/hsr2.151
   PubMedGoogle Scholar
• Pawlotsky J-M, Negro F, Aghemo A. EASL recommendations on treatment of hepatitis C: final update of the series(☆). J Hepatol. 2020 Nov;73(5):1170–1218. doi: 10.1016/j.jhep.2020.08.018
   PubMed Web of Science ®Google Scholar
• Yen H-H, Su P-Y, Liu IL, et al. Direct-acting antiviral treatment for hepatitis C virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients. PeerJ. 2021 Mar 16;9:e10944.
   PubMed Web of Science ®Google Scholar
• Atsukawa M, Kondo C, Kawano T, et al. Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease. J Nippon Med School. 2021;88(3):163–170. 10.1272/jnms.JNMS.2021_88-316
   PubMed Web of Science ®Google Scholar
• Parmar P, Shafran SD, Borgia SM, et al. Hepatitis C direct-acting antiviral outcomes in patients 75 years and older. JGH Open. 2021 Feb;5(2):253–257.
   PubMed Web of Science ®Google Scholar
• Jamall IS, Yusuf S, Azhar M, et al. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol. 2008 Nov 21;14(43):6627–6631. doi: 10.3748/wjg.14.6627
   PubMed Web of Science ®Google Scholar
• Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 3):1–12.
   PubMedGoogle Scholar
• Tsukiyama-Kohara K, Kohara M Hepatitis C virus: viral quasispecies and genotypes. Int J Mol Sci. 2018;19(1):23. doi: 10.3390/ijms19010023
   Web of Science ®Google Scholar
• Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol. 1999 Oct 01;7(10):402–410.
   PubMed Web of Science ®Google Scholar
• Lu J, Feng Y, Chen L, et al. Subtype-specific prevalence of hepatitis C virus NS5A resistance associated substitutions in mainland China. Front Microbiol. 2019;10:535. doi: 10.3389/fmicb.2019.00535
   PubMed Web of Science ®Google Scholar
• Rahimi P, Sharafi H, Bahramali G, et al. Prevalence of naturally-occurring NS5A and NS5B resistance-associated substitutions in Iranian patients with chronic hepatitis C infection [original research]. Front Microbiol. 2021 Jan 28;11:11.
   Web of Science ®Google Scholar
• Smith D, Magri A, Bonsall D, et al. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology. 2019;69(5):1861–1872. doi: 10.1002/hep.29837
   PubMed Web of Science ®Google Scholar
• Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 2018 Mar 01;37:17–39.
   PubMed Web of Science ®Google Scholar
• Dietz J, Kalinina OV, Vermehren J, et al. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat. 2020 Oct;27(10):974–986.
   PubMed Web of Science ®Google Scholar
• Aldunate F, Echeverría N, Chiodi D, et al. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report. BMC Infect Dis. 2021 Apr 26;21(1):387. doi: 10.1186/s12879-021-06080-0
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Hashmi AH, Khan A, et al. Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals. Front Pharmacol. 2022;13:894460. doi: 10.3389/fphar.2022.894460
   PubMed Web of Science ®Google Scholar
• Gupta N, Manirambona L, Shumbusho F, et al. Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. Lancet Gastroenterol Hepatol. 2022;7(6):542–551. doi: 10.1016/S2468-1253(21)00399-X
   PubMed Web of Science ®Google Scholar
• Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019;71(4):666–672. doi: 10.1016/j.jhep.2019.06.002
   PubMed Web of Science ®Google Scholar
• Wilson E, Covert E, Hoffmann J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019 Sep;71(3):498–504.
   PubMed Web of Science ®Google Scholar
• Ruane P, Strasser SI, Gane EJ, et al. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study. J Viral Hepat. 2019 Jun;26(6):770–773.
   PubMed Web of Science ®Google Scholar
• Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017 Aug;66(2):389–397.
   PubMed Web of Science ®Google Scholar
• Poordad F, Pol S, Asatryan A, et al. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Hepatology. 2018;67(4):1253–1260. doi: 10.1002/hep.29671
   PubMed Web of Science ®Google Scholar
• Suda G, Nakai M, Sho T, et al. The successful retreatment with Glecaprevir and pibrentasvir of genotype 1 or 2 HCV-infected hemodialysis patients who failed to respond to NS5A and protease inhibitor treatment. Intern Med. 2019 Apr 1;58(7):943–947. doi: 10.2169/internalmedicine.2077-18
   PubMed Web of Science ®Google Scholar
• Shen C, Fan H, Ge Z, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med. 2020;7:592472. doi: 10.3389/fmed.2020.592472
   Web of Science ®Google Scholar
• Gottwein JM, Pham LV, Mikkelsen LS, et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants. Gastroenterology. 2018 Apr 01;154(5):1435–1448. doi: 10.1053/j.gastro.2017.12.015
   PubMed Web of Science ®Google Scholar
• Arora R, Martin MT, Boike J, et al. Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment. World J Hepatol. 2023 Feb 27;15(2):318–320. doi: 10.4254/wjh.v15.i2.318
   PubMedGoogle Scholar
• Tergast TL, Kordecki N, Ohlendorf V, et al. Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure. Z Gastroenterol. 2022 Jun;60(6):959–962.
   PubMedGoogle Scholar
• Alimohammadi A, Conway B, Yamamoto L. Glecaprevir/Pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance. BMJ Case Rep. 2020;13(2):e233098. doi: 10.1136/bcr-2019-233098
   PubMedGoogle Scholar
• Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Internal Med. 2000;160(22):3365–3373. doi: 10.1001/archinte.160.22.3365
   PubMed Web of Science ®Google Scholar
• Operskalski EA, Kovacs A. HIV/HCV Co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Current HIV/AIDS Reports. 2011 Mar 01;8(1):12–22.
   PubMedGoogle Scholar
• Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected person. Ann Intern Med. 2003 Feb 4;138(3):197–207.
   PubMed Web of Science ®Google Scholar
• Mangia A, Milligan S, Khalili M, et al. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: integrated analysis of 12 clinical practice cohorts. J Hepatol. 2019 Apr 01;70(1, Supplement):e2–e3. doi: 10.1016/S0618-8278(19)30003-9
   Web of Science ®Google Scholar
• Sun HY, Cheng CY, Lin CY, et al. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol. 2022 Mar 21;28(11):1172–1183. doi: 10.3748/wjg.v28.i11.1172
   PubMed Web of Science ®Google Scholar
• Mohamed IELK, El-Saeed KM, Al-Sadik MH, et al. Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients. Egyptian Liver J. 2021 Apr 09;11(1):26. doi: 10.1186/s43066-021-00089-5
   Google Scholar
• MacíMacíAs J, Monge P, Mancebo M, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med. 2017 Aug;18(7):445–451.
   PubMed Web of Science ®Google Scholar
• MacíMacíAs J, Monge P, Mancebo M, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med. 2017;18(7):445–451. doi: 10.1111/hiv.12471
   PubMed Web of Science ®Google Scholar
• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. [cited 2024 Mar 10]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
   Google Scholar
• Huarez B, Hernández-Vásquez A, Azañedo D, et al. Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis. Arch Virol. 2022 Dec;167(12):2653–2664.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019 Apr;95(4):939–947.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Messa P. The epidemiology of HCV infection in patients with advanced CKD/ESRD: a global perspective. Semin Dial. 2019 Mar;32(2):93–98. doi: 10.1111/sdi.12757
   PubMed Web of Science ®Google Scholar
• Hsu C-K, Lai T-S, Chen Y-T, et al. Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals. Sci Rep. 2021 Aug 25;11(1):17197. doi: 10.1038/s41598-021-96782-x
   PubMed Web of Science ®Google Scholar
• Sise ME, Chute DF, Oppong Y, et al. Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease. Kidney Int. 2020 Jan;97(1):193–201.
   PubMed Web of Science ®Google Scholar
• de José A P, Carbayo J, Pocurull A, et al. Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study. Clin Kidney J. 2020;14(2):586–592. doi: 10.1093/ckj/sfz178
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Hepatitis C virus and mortality among patients on dialysis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019 Jun 01;43(3):244–254.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012 Sep;19(9):601–607. doi: 10.1111/j.1365-2893.2012.01633.x
   PubMed Web of Science ®Google Scholar
• Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019 Oct 01;71(4):660–665. doi: 10.1016/j.jhep.2019.05.028
   PubMed Web of Science ®Google Scholar
• Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant. 2022 Nov 23;37(12):2327–2334.
   PubMed Web of Science ®Google Scholar
• Hernández-Conde M, Calleja JL. Editorial: clinical impact of sofosbuvir renal toxicity—more light on the way. Aliment Pharmacol Ther. 2022;55(8):1052–1053. doi: 10.1111/apt.16861
   PubMed Web of Science ®Google Scholar
• Li M, Chen J, Fang Z, et al. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virol J. 2019 Mar 14;16(1):34. doi: 10.1186/s12985-019-1140-x
   PubMedGoogle Scholar
• Caro L, Wenning L, Feng HP, et al. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur J Clin Pharmacol. 2019 May;75(5):665–675.
   PubMed Web of Science ®Google Scholar
• Choi DT, Puenpatom A, Yu X, et al. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 Feb;174:104698. doi: 10.1016/j.antiviral.2019.104698
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-Infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394–2395. doi: 10.1056/NEJMc1705221
   PubMed Web of Science ®Google Scholar
• Molnar MZ, Azhar A, Tsujita M, et al. Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes. Am J Kidney Dis. 2021 May;77(5):739–747.e1.
   PubMed Web of Science ®Google Scholar
• Khullar V, Firpi RJ. Hepatitis C cirrhosis: new perspectives for diagnosis and treatment. World J Hepatol. 2015 Jul 18;7(14):1843–1855.
   PubMedGoogle Scholar
• Zhai M, Long J, Liu S, et al. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017. Aging (Albany NY). 2021 Jan 12;13(1):279–300. doi: 10.18632/aging.104127
   PubMedGoogle Scholar
• Wyles D, Poordad F, Wang S, et al. Glecaprevir/Pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology. 2018 Feb;67(2):514–523.
   PubMed Web of Science ®Google Scholar
• Esteban R, Pineda JA, Calleja JL, et al. Efficacy of Sofosbuvir and Velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018 Oct;155(4):1120–1127.e4.
   PubMed Web of Science ®Google Scholar
• Mansour D, McPherson S. Management of decompensated cirrhosis. Clin Med. 2018 Apr 1;18(Suppl 2):s60–s65.
   PubMed Web of Science ®Google Scholar
• Angeli P, Bernardi M, Villanueva C. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406–460. doi: 10.1016/j.jhep.2018.03.024
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Coppola C, et al. Efficacy of the “first wave” direct acting antivirals against HCV infection: results from the Italian LINA (liver network activity) cohort. New Microbiol. 2019 Apr;42(2):94–100.
   PubMed Web of Science ®Google Scholar
• Buonomo AR, Scotto R, Coppola C, et al. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore). 2020 Feb;99(6):e18948.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628. doi: 10.1056/NEJMoa1512614
   PubMed Web of Science ®Google Scholar
• Lu M, Wu K-H, Li J, et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019;26(10):1210–1217. doi: 10.1111/jvh.13162
   PubMed Web of Science ®Google Scholar
• Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016 Jun 01;16(6):685–697. doi: 10.1016/S1473-3099(16)00052-9
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep 01;149(3):649–659. doi: 10.1053/j.gastro.2015.05.010
   PubMed Web of Science ®Google Scholar
• Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (liver network activity-LINA cohort). Hepatol Int. 2019 Jan;13(1):66–74.
   PubMed Web of Science ®Google Scholar
• Mak LY, Seto WK, Lai CL, et al. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol. 2018 May;14(5):483–491.
   PubMed Web of Science ®Google Scholar
• Berkan-Kawińska A, Piekarska A, Janczewska E, et al. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: epi-Ter2 study. Liver Int. 2021 Aug;41(8):1789–1801.
   PubMed Web of Science ®Google Scholar
• Patel S, Martin MT, Flamm SL. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int. 2021;41(12):3024–3027. doi: 10.1111/liv.15075
   PubMed Web of Science ®Google Scholar
• Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019 Jan;54(1):87–95.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Aronsohn A, Price J, et al., American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Pane. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. 2023. doi: 10.1093/cid/ciad319
   Google Scholar
• Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009 Jul;50(1):46–55.
   PubMed Web of Science ®Google Scholar
• Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003 Jan 3;278(1):591–607. doi: 10.1074/jbc.M204241200
   PubMed Web of Science ®Google Scholar
• Balagopal A, Thio CL. When viruses collide: hepatitis B virus reactivation after hepatitis C treatment. J Clin Investig. 2020 Jun 01;130(6):2823–2826.
   PubMed Web of Science ®Google Scholar
• Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(3):172–180. doi: 10.1016/S2468-1253(18)30002-5
   PubMed Web of Science ®Google Scholar
• Hui VW, Au CL, Lam ASM, et al. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study. Hepatol Int. 2022 Dec;16(6):1318–1329.
   PubMed Web of Science ®Google Scholar
• Néant N, Solas C. Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection. Int J Antimicrob Agents. 2020 Jul;56(1):105571. doi: 10.1016/j.ijantimicag.2018.10.014
   PubMed Web of Science ®Google Scholar
• Macken L, Gelson W, Priest M, et al. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. J Med Virol. 2019 Nov;91(11):1979–1988.
   PubMed Web of Science ®Google Scholar
• Scotto R, Buonomo AR, De Pascalis S, et al. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver network activity’ (LINA) cohort update results. Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1057–1063.
   PubMed Web of Science ®Google Scholar
• Guardigni V, Badia L, Conti M, et al. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. World J Hepatol. 2017 Dec 8;9(34):1270–1277. doi: 10.4254/wjh.v9.i34.1270
   PubMedGoogle Scholar
• Pillai AA, Anania FA, Pearlman BL. Caution: reactivation of hepatitis B during hepatitis C treatment with direct-acting antiviral therapy. Am J Gastroenterol. 2016 Dec;111(12):1854–1856. doi: 10.1038/ajg.2016.422
   PubMed Web of Science ®Google Scholar